DeepMed Research

Antithrombin III human

Generic Name: Antithrombin III human

Brand Names: Thrombate III

Drug Type: Biotech

CAS Number: 9000-94-6

Unique Ingredient Identifier: T0LTO7L82X

Background: A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.

Indication: Antithrombin III human is a human antithrombin (AT) indicated in patients with hereditary antithrombin deficiency for the treatment and prevention of thromboembolism and prevention of peri-operative and peri-partum thromboembolism

Associated Conditions: Hereditary antithrombin III deficiency

Clinical Trials

Efficacy of Atenativ in Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

Phase 3

Recruiting

Conditions: Congenital Antithrombin Deficiency

Interventions: Drug: Atenativ

First Posted Date: 2021-06-08

Last Posted Date: 2025-02-04

Lead Sponsor: Octapharma

Target Recruit Count: 38

Registration Number: NCT04918173

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States

and more 20 locations

Antithrombin III and Post-liver Transplantation Acute Kidney Injury

Completed

Conditions: Liver Transplantation and Antithrombin

Interventions: Drug: Antithrombin III

First Posted Date: 2021-06-03

Last Posted Date: 2021-06-03

Lead Sponsor: Asan Medical Center

Target Recruit Count: 2395

Registration Number: NCT04912193

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Antithrombin III in Infectious Disease Caused by COVID-19

Phase 2

Terminated

Conditions: Antithrombin III Deficiency
Covid19

Interventions: Drug: Antithrombin III

First Posted Date: 2021-05-24

Last Posted Date: 2022-09-07

Lead Sponsor: Enrique Ginzburg

Target Recruit Count: 52

Registration Number: NCT04899232

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection

Completed

Conditions: Covid19

Interventions: Drug: Antithrombin III

First Posted Date: 2020-12-03

Last Posted Date: 2023-10-10

Lead Sponsor: Octapharma

Target Recruit Count: 300

Registration Number: NCT04651400

Locations: 🇸🇪
ECMO Centre Karolinska, Stockholm, Sweden
🇩🇪
Octapharma Research Site, Essen, Germany

Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis

Phase 1

Withdrawn

Conditions: Cirrhosis, Liver
Portal Vein Thrombosis

Interventions: Drug: Antithrombin III
Other: Placebo

First Posted Date: 2019-08-13

Last Posted Date: 2022-03-10

Lead Sponsor: Jonathan Stine

Registration Number: NCT04055389

Locations: 🇺🇸
Penn State College of Medicine, Hershey, Pennsylvania, United States

Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support

Phase 1

Completed

Conditions: Extracorporeal Membrane Oxygenation Complication
Cardiopulmonary Bypass

Interventions: Drug: Antithrombin III

First Posted Date: 2015-12-16

Last Posted Date: 2019-01-25

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 27

Registration Number: NCT02631174

Locations: 🇺🇸
Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States

Atenativ Effect on Uterine Blood Flow and Preeclampsia

Phase 4

Withdrawn

Conditions: Antithrombin III Deficiency

Interventions: Drug: Atenativ

First Posted Date: 2014-10-30

Last Posted Date: 2017-09-26

Lead Sponsor: Vastra Gotaland Region

Registration Number: NCT02278575

Locations: 🇸🇪
Dept Obstetrics, Sahlgrenska University Hospital, Gothenburg, Sweden

Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)

Phase 1

Terminated

Conditions: Congenital Heart Disease

Interventions: Drug: Antithrombin III
Drug: Placebo

First Posted Date: 2012-10-03

Last Posted Date: 2016-03-22

Lead Sponsor: University of Rochester

Target Recruit Count: 6

Registration Number: NCT01698567

Locations: 🇺🇸
Michael Eaton, MD, Rochester, New York, United States

Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery

Phase 3

Completed

Conditions: Cardiopulmonary Bypass

Interventions: Other: Saline Placebo
Drug: Antithrombin III

First Posted Date: 2012-02-10

Last Posted Date: 2015-01-07

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 18

Registration Number: NCT01530737

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery

Phase 4

Conditions: Mitral Valve Stenosis
Aortic Valve Insufficiency
Aortic Valve Stenosis
Mitral Valve Insufficiency
Acute Coronary Syndrome

Interventions: Drug: antithrombin III

First Posted Date: 2010-09-14

Last Posted Date: 2010-09-15

Lead Sponsor: University of Bari

Target Recruit Count: 90

Registration Number: NCT01201070

Locations: 🇮🇹
Azienda Ospedaliero-Universitaria Policlinico, Bari, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy